At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 49 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Placebo and Tezepelumab for Healthy Volunteers. Completed, enrolled 49 participants.
Detailed Summary
The primary objective is to evaluate the safety, tolerability, and immunogenicity of multiple-dose administration of tezepelumab in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartSep 2009
Primary CompletionJan 2011
TodayJul 2026
First PostedSep 4, 2009
Enrollment StartSep 15, 2009
Primary CompletionJan 9, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.8 years ago
Interventions
Placebodrug
Administered by subcutaneous or intravenous injection.
Tezepelumabdrug
Administered by subcutaneous or intravenous injection